InvestorsHub Logo
Followers 10
Posts 500
Boards Moderated 0
Alias Born 09/04/2014

Re: None

Tuesday, 02/13/2018 8:10:47 PM

Tuesday, February 13, 2018 8:10:47 PM

Post# of 1121
$ACST Points from the third quarter fiscal year 2018 financials.

We expect to continue advancing our potential best-in-class prescription omega-3 product for the treatment of severe hypertriglyceridemia through the patient enrollment process in 2018, and beyond to expected top line results by the end of 2019



We also entered into a non-binding term sheet agreement this quarter with a leading Chinese pharmaceutical company for the development and commercialization of CaPre in certain Asian countries. This partnership is the first step in our worldwide strategy to maximize the value of our asset.



Financing completed to support CaPre Phase 3 trials



The first clinical sites were activated and patient enrollment initiated for the CaPre Phase 3 program



Progressed commercialization agreement with leading Chinese pharmaceutical partner



http://www.acastipharma.com/wp-content/uploads/Acasti-Pharma-Reports-Third-Quarter-FY-2018-Financial-Results.pdf

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ACST News